
Kimberly Chong
Examiner (ID: 8669, Phone: (571)272-3111 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1636, 1635, 1674 |
| Total Applications | 2007 |
| Issued Applications | 1153 |
| Pending Applications | 209 |
| Abandoned Applications | 674 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18326488
[patent_doc_number] => 20230124616
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => COMPOUNDS AND METHODS FOR MODULATING KCNQ2
[patent_app_type] => utility
[patent_app_number] => 17/908135
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28086
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17908135
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/908135 | COMPOUNDS AND METHODS FOR MODULATING KCNQ2 | Mar 4, 2021 | Pending |
Array
(
[id] => 18346567
[patent_doc_number] => 20230134677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF USHER SYNDROME
[patent_app_type] => utility
[patent_app_number] => 17/908199
[patent_app_country] => US
[patent_app_date] => 2021-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14302
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17908199
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/908199 | ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF USHER SYNDROME | Mar 2, 2021 | Pending |
Array
(
[id] => 18391706
[patent_doc_number] => 20230159924
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/905442
[patent_app_country] => US
[patent_app_date] => 2021-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905442
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | Mar 1, 2021 | Pending |
Array
(
[id] => 18352625
[patent_doc_number] => 20230140736
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => ANTISENSE NUCLEIC ACID INDUCING SKIPPING OF EXON 51
[patent_app_type] => utility
[patent_app_number] => 17/802720
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14965
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802720
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802720 | ANTISENSE NUCLEIC ACID INDUCING SKIPPING OF EXON 51 | Feb 25, 2021 | Pending |
Array
(
[id] => 17406080
[patent_doc_number] => 11246941
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-15
[patent_title] => Compositions and methods of treating muscle atrophy and myotonic dystrophy
[patent_app_type] => utility
[patent_app_number] => 17/187650
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 69
[patent_figures_cnt] => 104
[patent_no_of_words] => 62934
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187650
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/187650 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | Feb 25, 2021 | Issued |
Array
(
[id] => 17330260
[patent_doc_number] => 11220713
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-11
[patent_title] => MicroRNAs as biomarkers for endometriosis
[patent_app_type] => utility
[patent_app_number] => 17/184894
[patent_app_country] => US
[patent_app_date] => 2021-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 25981
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184894
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/184894 | MicroRNAs as biomarkers for endometriosis | Feb 24, 2021 | Issued |
Array
(
[id] => 19763328
[patent_doc_number] => 12221607
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-11
[patent_title] => Multi-targeted single entity conjugates
[patent_app_type] => utility
[patent_app_number] => 17/181870
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 27
[patent_no_of_words] => 52937
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181870
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/181870 | Multi-targeted single entity conjugates | Feb 21, 2021 | Issued |
Array
(
[id] => 18298654
[patent_doc_number] => 20230108340
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => METHODS FOR REDUCING HTT EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/800785
[patent_app_country] => US
[patent_app_date] => 2021-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18790
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -81
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800785
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/800785 | METHODS FOR REDUCING HTT EXPRESSION | Feb 18, 2021 | Abandoned |
Array
(
[id] => 17214833
[patent_doc_number] => 20210348170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
[patent_app_type] => utility
[patent_app_number] => 17/177947
[patent_app_country] => US
[patent_app_date] => 2021-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37238
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17177947
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/177947 | Compositions and methods for treating beta-hemoglobinopathies | Feb 16, 2021 | Issued |
Array
(
[id] => 18636411
[patent_doc_number] => 11760999
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-19
[patent_title] => RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
[patent_app_type] => utility
[patent_app_number] => 17/174452
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 30
[patent_no_of_words] => 17113
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174452
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/174452 | RAAV-based compositions and methods for treating amyotrophic lateral sclerosis | Feb 11, 2021 | Issued |
Array
(
[id] => 17185472
[patent_doc_number] => 20210332357
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => Protecting RNAs from Degradation Using Engineered Viral RNAs
[patent_app_type] => utility
[patent_app_number] => 17/173354
[patent_app_country] => US
[patent_app_date] => 2021-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13610
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17173354
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/173354 | Protecting RNAs from degradation using engineered viral RNAs | Feb 10, 2021 | Issued |
Array
(
[id] => 18692975
[patent_doc_number] => 20230323343
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => CLOSED LINEAR DNA WITH MODIFIED NUCLEOTIDES
[patent_app_type] => utility
[patent_app_number] => 17/796532
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16001
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796532
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/796532 | CLOSED LINEAR DNA WITH MODIFIED NUCLEOTIDES | Jan 28, 2021 | Pending |
Array
(
[id] => 17214829
[patent_doc_number] => 20210348166
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => IMMUNOTHERAPY OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/150668
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12114
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150668
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150668 | IMMUNOTHERAPY OF CANCER | Jan 14, 2021 | Abandoned |
Array
(
[id] => 17141991
[patent_doc_number] => 20210310003
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
[patent_app_type] => utility
[patent_app_number] => 17/144456
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16479
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144456
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/144456 | Exogenous control of mammalian gene expression through aptamer-mediated modulation of polyadenylation | Jan 7, 2021 | Issued |
Array
(
[id] => 18492400
[patent_doc_number] => 11697811
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-11
[patent_title] => Oligomers
[patent_app_type] => utility
[patent_app_number] => 17/143799
[patent_app_country] => US
[patent_app_date] => 2021-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 30
[patent_no_of_words] => 16111
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17143799
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/143799 | Oligomers | Jan 6, 2021 | Issued |
Array
(
[id] => 19234036
[patent_doc_number] => 20240191228
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF NEUROLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/789750
[patent_app_country] => US
[patent_app_date] => 2021-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15866
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17789750
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/789750 | ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF NEUROLOGICAL DISORDERS | Jan 4, 2021 | Abandoned |
Array
(
[id] => 18240697
[patent_doc_number] => 20230073008
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => ANTISENSE NUCLEIC ACID THAT INDUCES SKIPPING OF EXON 50
[patent_app_type] => utility
[patent_app_number] => 17/788826
[patent_app_country] => US
[patent_app_date] => 2020-12-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12092
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788826
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/788826 | ANTISENSE NUCLEIC ACID THAT INDUCES SKIPPING OF EXON 50 | Dec 24, 2020 | Abandoned |
Array
(
[id] => 16762694
[patent_doc_number] => 20210108275
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-15
[patent_title] => MATERIALS AND METHODS FOR BLADDER CANCER DETECTION
[patent_app_type] => utility
[patent_app_number] => 17/131943
[patent_app_country] => US
[patent_app_date] => 2020-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8595
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17131943
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/131943 | MATERIALS AND METHODS FOR BLADDER CANCER DETECTION | Dec 22, 2020 | Abandoned |
Array
(
[id] => 19717549
[patent_doc_number] => 12203073
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-21
[patent_title] => Plant viral RNA delivery nanoparticles and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/129463
[patent_app_country] => US
[patent_app_date] => 2020-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 13
[patent_no_of_words] => 15888
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17129463
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/129463 | Plant viral RNA delivery nanoparticles and uses thereof | Dec 20, 2020 | Issued |
Array
(
[id] => 16762629
[patent_doc_number] => 20210108210
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-15
[patent_title] => MUCOSAL HEALING PROMOTER
[patent_app_type] => utility
[patent_app_number] => 17/116067
[patent_app_country] => US
[patent_app_date] => 2020-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8307
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17116067
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/116067 | MUCOSAL HEALING PROMOTER | Dec 8, 2020 | Abandoned |